TFX

$109.00

Market ClosedAs of Mar 17, 8:00 PM UTC

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$109.00
Potential Downside
78%
Whystock Fair Value$23.99
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Instruments & Supplies

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
83.21
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Strong income play. Yield provides a meaningful total return floor.
125.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
1.58%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.98

Recent News

StockStory
Mar 9, 2026

3 Reasons TFX is Risky and 1 Stock to Buy Instead

Over the last six months, Teleflex’s shares have sunk to $113.26, producing a disappointing 13% loss - a stark contrast to the S&P 500’s 4.8% gain. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
StockStory
Mar 6, 2026

Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 2, 2026

Teleflex Reshapes Portfolio With US$1b Plan For EPS And Balance Sheet

Teleflex (NYSE:TFX) plans to divest selected businesses and use about US$1b for share repurchases and debt reduction. The company expects these moves to sharpen its portfolio focus and support future earnings per share. Management is positioning the balance sheet for greater financial flexibility following the divestitures. Teleflex, a medical technology company, generates revenue from devices used in critical care and surgical settings. For investors, portfolio changes on this scale can...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 1, 2026

Teleflex Q4 Earnings Call Highlights

Teleflex (NYSE:TFX) outlined a major portfolio transition and provided an updated financial framework as the company reported year-end 2025 results, emphasizing the planned divestitures of its Acute Care, Interventional Urology, and OEM businesses and the creation of a more focused “RemainCo.” Manag

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 27, 2026

TFX Q4 Earnings & Revenues Miss, Margins Down, Stock Up in After-Market

Teleflex Q4 earnings and revenues miss estimates as margins shrink, but shares rise 1.7% after hours amid 2026 growth guidance and portfolio reshuffle.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.